Clinical

Explore the latest findings from the KATHERINE, PATINA, and HER2CLIMB-05 trials, highlighting advancements and challenges in breast cancer treatment.

Steven Stoner, PharmD, advocates for integrating patient-reported outcomes and digital monitoring to identify early treatment failure and justify utilizing highly effective therapies like dextromethorphan-bupropion sooner.

On average, patients with multiple prior dermatology visits still scored below 75% when identifying common skin cancer terms, underscoring the need for clearer patient-physician communication.

Methylprednisolone was more effective in treating thymoma compared with docetaxel but adverse effects were more common.

Explore the unique mechanisms of bispecific antibodies and their rapid availability compared to CAR T-cell therapies in cancer treatment.

Explore the unique mechanisms of bispecific antibodies versus CAR T-cell therapies in treating multiple myeloma and their clinical implications.

Patient–physician collaboration ensures trials reflect outcomes that matter to patients, according to Debra Patt, MD, PhD, MBA, MPH.

Last week, OpenAI launched AI tools for health care organizations, including ChatGPT for Healthcare, designed to improve care and streamline administrative tasks.

Risk-based vaccination strategies and clinical pathway integration could improve coverage and strengthen future influenza preparedness, according to Marco del Riccio, MD.

Amivantamab-vmjw combined with FOLFOX/FOLFIRI delivers encouraging response rates, durable benefit, and manageable safety.

Panelists discuss how emerging therapies targeting new pathways may revolutionize schizophrenia management.

Panelists discuss how optimizing safety and cost-efficiency are central to improving adherence and overall health care value.

Yara Abdou, MD, emphasizes that addressing fertility, survivorship, and quality of life is key to improving outcomes for young patients with breast cancer.

Although influenza vaccine uptake remains low, improving access, recommendations, and trust may help close coverage gaps.

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant breakthrough in treatment options.

Reduced doses and shorter durations of venetoclax can enhance treatment outcomes and reduce adverse events in acute myeloid leukemia (AML).

Patients with unresectable stage III non–small cell lung cancer (NSCLC) had previously received neoadjuvant chemoimmunotherapy.

Circulating tumor DNA shows promise in detecting esophageal cancer recurrence earlier than traditional methods, enhancing posttreatment surveillance.

Asian women with breast cancer receiving chemotherapy had the highest persistent chemotherapy-induced alopecia (PCIA) incidence and alopecia-related distress vs their White, Black, and Hispanic or Latino peers.

Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and treatment access.

Experts explore HER2 mutations and the critical role of comprehensive molecular profiling in optimizing treatment for non-small cell lung cancer patients.

Multidisciplinary care helps manage cardiac risks in breast cancer, allowing patients to continue treatment safely, says Eric H. Yang, MD.

EHR penicillin allergy flags do not often match allergist assessments, highlighting the need for improved evaluation processes.

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient outcomes.

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with longer PFS, suggesting T-cell composition may serve as a biomarker to guide patient selection.